Introduction: In a previous meta-analysis, we derived pooled estimates for the association of left ventricular mass (LVM) and hypertrophy (LVH), as diagnosed by electrocardiography or echocardiography, with the ACE D/I polymorphism. We updated this meta-analysis until May 2009 only considering echocardiographic phenotypes. Methods: We computed pooled estimates from a random-effects model. Results: Across 38 studies, both DD homozygotes (n = 2440) and DI heterozygotes (n = 4310) had higher (p ≤ 0.002) LVM or LVM index than II homozygotes (n = 2229). Across 21 studies with available data, this was due to increased mean wall thickness (MWT) with no difference in left ventricular internal diameter (LVID). Standardised differences (DD versus II) were 0.39 (p < 0.001) for LVM, 0.34 (p = 0.009) for MWT, and 0.066 (p = 0.26) for LVID. Across 16 studies (4894 participants), the pooled odds ratios of LVH (versus II homozygotes) were 1.11 (p = 0.29) and 1.02 (p = 0.88) for the DD and DI genotypes, respectively. Sensitivity analyses were confirmatory. Conclusions: Our meta-analysis supports the hypothesis that the enhanced ACE activity associated with the D allele is associated with higher LV mass. Smaller sample size might explain the lack of significant association with LVH.
Introduction
Left ventricular hypertrophy (LVH) is a risk factor for cardiovascular morbidity and mortality. Studies in twins 1,2 and populations [3] [4] [5] [6] showed that left ventricular mass (LVM) is under genetic control. Heritability estimates ranged from 30% to 70%. [1] [2] [3] [4] [5] [6] The angiotensin-converting enzyme (ACE) deletion/insertion polymorphism (D/I) is among the genotypes most frequently studied in relation to LVM, because compared with the II genotype circulating 7, 8 and tissue 9 ACE levels are highest in DD homozygotes and intermediate in DI heterozygotes. Moreover, drugs are available to interfere with the increased activity of ACE.
LVM is a continuous trait influenced by complex interactions between genetic, environmental and lifestyle factors. It is therefore not surprising that studies of the association between LVM and the ACE D/I polymorphism reported divergent results. In a previous meta-analysis, 10 we derived pooled estimates for the association between LVH and the ACE D/I polymorphism. We found that in untreated hypertensive patients LVM was higher in DD than in II homozygotes. In view of the discrepancies in the literature and the possibility of pharmacological intervention based on genotype, we updated this meta-analysis until May 2009. To remove variability in the phenotype of interest, for the current study, we only considered echocardiographic measurement of LVM.
Selection criteria
To be eligible, studies had to meet all positive selection criteria. The reports had to include a minimum of 50 subjects with at least one of the following echocardiographically measured traits: LVM, left ventricular mass index (LVMI) indexed to body surface area (BSA) or height, left ventricular end-diastolic diameter (LVID), mean wall thickness (MWT) or LVH as a dichotomous trait. Eligible articles had to provide sufficient information to extract or compute for each ACE D/I genotype the number of subjects, the mean and standard deviation (SD) of continuous left ventricular traits, number of subjects with and without LVH. Such information should be available for all study participants or for subgroups. Eligible studies were cross-sectional studies of population samples or selected groups of patients, volunteers, healthy subjects, athletes, or had a case-control design.
We excluded from our systematic review studies that involved non-echocardiographically measured phenotypes, such as electrocardiographically defined LVH or LVM assessed by magnetic resonance imaging (MRI). We disregarded studies in patients with specific disorders, such as hypertrophic cardiomyopathy, aortic valve stenosis, myocardial infarction, renovascular diseases, or renal dysfunction. We also excluded data based on follow-up studies testing pharmacological interventions according to ACE D/I genotype, as well as repeated data.
Data extraction
The articles were ordered by year of publication and the name of the first author, given a unique identification number, and entered into a dedicated literature database, using Reference Manager, version 12.0.1 (Thomson Reuters; http://www.refman.com). One investigator (YJ) read all papers, extracted and computerised the relevant information, and provided copies of the papers to the senior author (JAS), who checked the data extraction and summary statistics. Disagreements were resolved by discussion.
For all studies included in this review, the following information was retrieved: source of recruitment, ethnicity, sex, age, percentage of patients with hypertension, treatment status with regard to hypertension, the allelic and genotypic frequencies of the ACE D/I polymorphism, and LV phenotypes according to ACE D/I genotypes. Whenever possible, these results were extracted separately for women and men. Conversely, when the articles reported results by subgroups, we computed overall results for all subjects combined in one publication.
The methodology of ACE genotyping was considered as a possible confounder in the statistical analysis. ACE genotyping may rely on the plain amplification of DNA 7, 11 or on the amplification in the presence of 5% dimethyl sulfoxide (DMSO) 12,13 and/or insertion-specific primers. 14 Papers in which specific primers had been used were contrasted with the remainder of the reports. We also graded each article according to the impact factor of the journal at the time of publication. 15 For journals not listed at the time of publication in the Institute for Scientific Information database (Thompson Reuter), we used the impact factor of the year closest to the date of publication.
Flemish Study on Environment, Genes and Health Outcomes
We also included data from the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO). The Ethics Committee of the University of Leuven approved the FLEMENGHO study. 16, 17 From August 1985 until December 2005, we recruited a random sample of families from a geographically defined area in northern Belgium. We invited 652 participants for a follow-up examination, which included echocardiography, of whom 553 gave written informed consent (participation rate, 84.8%). We excluded 48 patients with cardiac disorders, 26 subjects with echocardiograms of insufficient quality, and 12 with missing genotypes. Thus, the number of FLEMENGHO subjects included in the current meta-analysis was 467.
Statistical analysis
We used SAS software (SAS Institute Inc., Cary, NC, USA) for entering extracted data into a manageable database and for subsequent statistical analysis. We expressed the central tendency and spread of continuous variables as mean and standard deviation, respectively. LVM was varyingly reported in absolute units LVM (g/m 2 ) or indexed to BSA (g/m 2 ) or body height (g/m or g/m 2 ). To assess between-group differences independent of the unit of measurement, we computed the mean standardised difference by subtracting the mean value of the trait of interest in II homozygotes from the corresponding mean in DD homozygotes or DI heterozygotes and by dividing this difference by the common across-group standard deviation. For studies with LVH as outcome, we computed odds ratios for the DD or DI genotypes versus II homozygotes. We used a random-effects model as implemented in the PROC MIXED procedure of the SAS package and the method of moments to compute pooled associations of continuous left ventricular traits with the ACE genotypes and pooled odds ratios, as described by Normand. 18 We assessed the null-hypothesis of homogeneity across individual studies by the Q test. 18 Pooled estimates were weighted by the inverse of the variance in individual studies.
We evaluated the influence of individual studies on pooled effect sizes by excluding one study at the time according to Tobias' method. 19 If the point estimate of the combined effect size with one study omitted lies outside the confidence interval of the overall estimate with all available studies contributing, then the study in question has an excessive influence. In a further sensitivity analysis, we calculated the pooled effect size of LVM or LVMI or odds of LVH in different subgroups. Moreover, we computed the pooled odds of LVH of the D versus I allele. We tested for publication bias, using the methods described by Egger et al. 20 In addition, we plotted the association size (continuous variables) or the natural logarithm of each study's odds ratio (LVH) against the logarithm of the sample size. If there is no publication bias, such plot must produce a funnel shape (funnel plot), because the points scatter around the true pooled value with the scattering narrowing as the sample size increases. We used a χ 2 -statistic to compare allelic frequencies between races. All p values are for twosided tests.
Results

Computerised database
The flow chart (figure 1) summarises the results of our literature search and the inclusion and exclusion of studies. Using the search terms outlined in the methods, the PubMed database generated 831 hits. After reading the abstract, we excluded 752 studies because they were out of focus, and 21 because they involved patients with specific diseases, such as hypertrophic cardiomyopathy, aortic valve stenosis, myocardial infarction, renovascular disease, or renal dysfunction. We did a full paper review of 58 studies. We excluded 16 studies, because all required information was not available (n = 8), or because LVM was assessed nonechocardiographically (n = 8). In addition to the studies retrieved from the literature search, we also included our own FLEMENGHO study. 16, 17 Of the 43 studies included in our meta-analysis, 16,21-62 five were population-based, 16,21-24 25 included pati ents, five were case-control studies of patients with hypertension [50] [51] [52] [53] or LVH, 54 four involved athletes, [59] [60] [61] [62] and four included healthy volunteers. [55] [56] [57] [58] All studies combined included 10,320 participants of Asian 25, 27, 30, 33, 36, 37, 39, 46, 47, 49, 54, 58 (n = 1806; 17.5%), African 27 (n = 16; 0.1%) or 16, 22, [24] [25] [26] 33, 43, 50, 51 ( Table S1 in the supplementary material).
Prevalence of the D allele
The overall prevalence of the D allele was 52.3%. The DD, DI and II genotypic frequencies were 28.2%, 48.1% and 23.7%, respectively. The null hypothesis of Hardy-Weinberg equilibrium was rejected in 11 studies. 24, 25, 27, 37, 39, 42, 44, 45, 49, 56, 62 In all studies combined, the allele frequency showed no obvious deviation from the Hardy-Weinberg equilibrium. The prevalence of the D allele was significantly lower (p < 0.001) in Asians (38.9%) than in Caucasians (55.0%).
Association with left ventricular structure in continuous analyses
Across studies, LVM was computed based on echocardiographic measurements following the criteria of the American Society of Echocardiography in 15 studies 16, 21, 23, 24, 28, 38, 42, [49] [50] [51] 55, 56, 59, 60, 62 and the Penn convention in 23 studies. 22, 25, 27, [29] [30] [31] [32] [33] [35] [36] [37] [39] [40] [41] [43] [44] [45] [46] [47] [48] 53, 58, 61 There was significant heterogeneity (Q = 86.1, p < 0.001) among the 38 studies (42 groups, 8979 subjects) that reported on LVM or LVMI. Compared with II homozygotes (n = 2229), both DD homozygotes (n = 2440) and DI heterozygotes (n = 4310) had higher ( p≤0.002) LVM or LVMI (table 1) . Along similar lines, across 21 studies (n = 4392), DD homozygotes (n = 1180) and DI heterozygotes (n = 2062) had higher MWT ( p≤0.034) than II homozygotes (n = 1150). In contrast, 21 studies combined (n = 5233), there was no association between LVID and the ACE D/I genotypes (p≥0.26). The standardised differences (DD versus II) were 0.39 (95% CI 0.20 to 0.59, p < 0.001) for LVM or LVMI, 0.34 (95% CI 0.085 to 0.59, p = 0.009) for MWT and 0.066 (95% CI −0.049 to 0.18, p = 0.26) for LVID.
In sensitivity analyses, we considered LVM or LVMI and the contrast between DD and II homozygotes. We first omitted one study at a time and recalculated the pooled association size for the remaining studies ( Figure S1 , panel A in the supplementary material). We did not identify any study that moved the point estimate outside the confidence interval for the overall estimate with all available studies. Table 2 summarises the sensitivity analyses according to ethnicity (Asians 25, 30, 33, 36, 37, 39, 46, 47, 49, 58 and Caucasians 16, [21] [22] [23] [24] 28, 29, 31, 32, 35, 38, [40] [41] [42] [43] [44] [45] 48, 50, 51, 53, 55, 56, [59] [60] [61] [62] ), gender (women 16, 21, 22, 25, 30, 42, 50, 56, 59 and men 16, 21, 22, 25, 30, 42, 50, 56, 59 ), normotension 21, 23, 50, 51, 53, 55, 56, [58] [59] [60] [61] [62] versus hypertension, [27] [28] [29] [30] [31] [32] [35] [36] [37] [38] [39] [40] [41] [42] [44] [45] [46] [47] [48] [49] [50] [51] treatment status for hypertension, 31, 32, 36, 40, 46, 48 genotyping methods (plain DNA amplification 23, 25, [29] [30] [31] [32] 36, 37, 39, 46, 48, 56, 62 16, 24, [37] [38] [39] [40] [41] [42] 44, 45, 47, 51, 53, 55, 56, 58, [60] [61] [62] [63] ). These sensitivity analyses showed consistency. In all strata, with the exception of women, DD homozygotes had greater LVM or LVMI than II homozygotes. The funnel plots searching for publication bias among the reviewed studies on LVM or LVMI revealed a deficit of small studies with negative results ( figure 2, panel A) . This visual impression was confirmed by Egger's test (p = 0.001).
Association with left ventricular hypertrophy as a categorical variable
The association between LVH and the ACE D/I genotype was addressed in 16 studies (17 groups, 4894 subjects). LVM was varyingly indexed to BSA in 12 studies 26, 28, 29, 34, [36] [37] [38] 40, 41, 45, 50, 52 (n = 2125), to height in two studies 21, 22 (n = 2525), or to height 2 in one study 27 (n = 64). In women, the cut-off points for LVH by using LVM indexed to BSA ranged from 104 26 to 110 28, 29, 34, 37, 40, 41, 45, 50 g/m 2 , while in men they ranged from 111 36 to 143 21, 22 g/m 2 .
Across 16 available studies ( Table 3 , Figure S2 in supplementary material), using II homozygotes as reference, the pooled odds ratio of LVH associated with the DD genotype (1.11, 95% CI 0.91 to 1.36, p = 0.29) or the DI genotype (1.02, 95% CI 0.75 to 1.39, p = 0.88) did not reach statistical significance. Compared with the I allele, the pooled risk of LVH associated with the D allele was 1.05 (95% CI 0.90 to 1.22, p = 0.52). Sensitivity analyses for echocardiographic LVH and the contrast between DD and II homozygotes appear in figure S1 and table 4. As before, we omitted one study at a time and recalculated the pooled odds for the remaining studies ( Figure S1, panel B in the supplementary material). We did not identify any study that moved the odds ratio outside the confidence interval for the overall odds with all available studies. We stratified according to ethnicity (Asians 36, 37, 54 and Caucasians 21, 22, 26, 28, 29, 34, 38, 40, 41, 45, 50, 52 ), presence of hypertension, [27] [28] [29] 34, [36] [37] [38] 40, 41, 45, 50 treatment status for hypertension, 34, 36, 40 genotyping methods (plain DNA amplification 26, 29, 36, 37, 54 versus other methods 21, 22, 27, 28, 34, 38, 40, 41, 45, 50, 52 ) and imaging methods (ASE criteria 21, 26, 28, 38, 50, 52 versus Penn convention 22, 27, 29, 34, 36, 37, 40, 41, 45 ), impact factor of the journal (<1, 36,41,45 1-3, 26,27,37,38,40,52,54 ≥ 3, 21,22,28,29,34,50 ) , study size (≤106 [median] 21, [27] [28] [29] 36, 38, 40, 45, 52 versus >106, 22, 26, 34, 37, 41, 50, 54 ) and year of publication (<1999 [median] 21, 22, [26] [27] [28] [29] 50 versus ≥1999, 34, [36] [37] [38] 40, 41, 45, 52, 54 ). These analyses did not reveal any significant association between the odds of LVH and the ACE D/I polymorphism with the exception of the odds ratios in never treated patients with hypertension (2.29; 95% CI, 1.05 to 4.99) 34, 36, 40 and in articles published in journals with an impact factor of 3 or more (1.46; 95% CI, 1.00 to 2.14; p = 0.053). 21, 22, 28, 29, 34, 50 The funnel plots searching for publication bias among the reviewed studies on LVH did not reveal a deficit of small negative studies ( figure 2, panel B ). This visual impression was confirmed by Egger's test (p = 0.66). In panel A, the lack of small studies with a negative association indicates publication bias (Egger's statistics, p = 0.001). In panel B, there is no indication for publication bias (Egger's statistics, p = 0.66). 
Discussion
The key finding of our meta-analysis was that in continuous analyses involving 38 studies and 8979 subjects, echocardiographic LVM or LVMI were higher in the presence of the ACE D allele. This increase was proportional to the number of D alleles and it was due to increased MWT without contribution of LVID. Sensitivity analyses showed that the association of LVM or LVMI with the ACE D/I polymorphism was consistent in Asians and Caucasians and did not depend on blood pressure status, genotyping or imaging methods, study size, journal impact factor, or year of publication. In categorical analyses, the risk of LVH was not significantly associated with the ACE D/I polymorphisms. However, a binary phenotype carries less information than a continuous trait, and only 16 studies, including 4894 subjects, reported on LVH. Moreover, criteria to diagnose LVH were different across studies. These factors probably decreased the statistical power to demonstrate association between the binary trait and the ACE D/I polymorphism in all studies combined. Of note, in never-treated hypertensive patients, in keeping with our previous results in untreated patients, 10 the association was significant. It also approached significance across 6 articles published in journals with an impact factor of 3 or more. The D/I polymorphism is a 287-bp sequence of DNA in intron 16 of the ACE gene. 7 In adults plasma ACE does not change with age and is only to a minor extent influenced by environmental or lifestyle factors. 64 Compared with II homozygotes, circulating ACE levels in plasma were nearly 30% and 60% higher in DI heterozygotes and DD homozygotes, respectively. 7 Moreover, DD homozygotes also have higher tissue levels of ACE. In T lymphocytes of 35 healthy volunteers, the mean ACE levels were 487 μU/mg protein (+76%), 362 μU/mg protein (+31%) and 277 μU/mg protein (reference) in carriers of the DD, DI and II genotypes, respectively. 9 Among 71 patients who died from noncardiac disorders, cardiac ACE activity was higher (p < 0.01) in subjects with the ACE DD genotype (12.7 mU/g wet wt) compared with subjects with the DI (8.7 mU/g) and the II (9.1 mU/g) genotypes. Because the D/I polymorphism is intronic, alleles in linkage disequilibrium with it and located within or near the ACE gene might explain the functionality of the polymorphism. 8, 65 However, introns are also involved in gene expression. For instance, Jonsson showed that expression of the human purine nucleoside phosphorylase gene (PNP) at the mRNA and protein level is dependent on the presence of intronic sequences and the level of PNP expression varied directly with the number of transfected introns. 66 ACE is playing a key role in renin-angiotensin system by catalysing the conversion of angiotensin I into angiotensin II, as well as by inhibiting the breakdown of bradykinin into inactive fragments. Angiotensin II is not only a potent vasoconstrictor, but also a direct growth factor. It has trophic properties, stimulates the growth of cardiomyocytes, and its effect on cardiac mass is partly independent of the effects on blood pressure. 67 Two meta-analyses 68, 69 of cli nical studies, one of which included non-randomised studies, 69 suggested that ACE inhibitors were more effective than beta-blockers and diuretics in regressing cardiac hypertrophy. Another meta-analysis of 80 randomised double-blind clinical trials in hypertensive patients 70 accounted for treatment duration and change in blood pressure. On treatment, LVM decreased by 13% (CI 8% to 18%) with angiotensin II receptor antagonists (ARBs), by 11% (9% to 13%) with calcium antagonists, by 10% (8% to 12%) with ACE inhibitors, by 8% (5% to 10%) with diuretics, and by 6% (3% to 8%) with beta-blockers. 70 In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, 71 losartan-based antihypertensive therapy resulted in greater regression of electrocardiographic LVH by Cornell voltage-duration product (−200 versus −69 mm × ms) and Sokolow-Lyon voltage (−2.5 versus −0.7 mm) criteria than did atenolol-based therapy. Fagard's recent meta-analysis, which was exclusively based on prospective randomised studies confirmed that beta-blockers induce less regression of LVM than the other of antihypertensive drugs. 72 The interpretation of these meta-analyses [68] [69] [70] and the LIFE trial 71 in the light of our current findings is difficult, because their results only account for randomised first-line therapy, but not for add-on treatment. ACE inhibitors and ARBs inhibit the renin system, but beta-blockers do as well, by reducing the renal secretion of renin, thereby decreasing circulating renin activity. Diuretics and to a lesser extent calcium channel blockers stimulate the renin system. To what extent the intrinsic renin-angiotensin system of the heart and blood pressure lowering per se 73 might play a role remains to be elucidated.
Most studies failed to find a significant association between the ACE D/I polymorphism and blood pressure. 74 It is therefore unlikely that the association of LVM or LVMI with the ACE D/I polymorphism is mediated through blood pressure, although we cannot exclude that D allele carriers might be responsive to the blood pressure load on the left ventricle. Pharmacogenetic studies in patients did not produce consistent results. All studies were retrospective and non-randomised. 38, 46, 47, 49 Two observed greater regression of LVMI on ACE inhibitors in DD compared with II homozygous hypertensive patients, 46, 47 whereas one produced opposite results, 49 another one produced null results. 38 An autopsy study of 693 consecutive patients, who died from non-cardiac disorders 75 demonstrated that heart weight indexed to BSA was greater in the DD homozygotes compared to both other ACE genotypes.
At usual or high levels of angiotensin I, the rate of angiotensin II generation depends on the substrate concentration. 76, 77 Renin is therefore usually viewed as the rate-limiting enzyme in the biochemical cascade leading to angiotensin II. 78 In humans, angiotensin II may also be produced by enzymes other than ACE, such as chymase in the heart. 79 Two small studies 80, 81 reported higher angiotensin I conversion rates in DD compared to II carriers, whereas two other studies did not find significant differences in the conversion rates between the ACE D/I genotypes. 82, 83 In a large epidemiological study, plasma levels of (pro)renin, angiotensinogen and aldosterone did not differ according to the ACE D/I genotypes. 82 The present results have to be interpreted within the context of their limitations. First, we found publication bias for studies reporting on the association of LVM or LVMI with the ACE genotype. This, in turn, may have led to some degree of overestimation of the pooled association of LVM or LVMI with the ACE D/I polymorphism. Second, there was heterogeneity between studies. We addressed this issue by computing pooled estimates from a random effects model. Moreover, sensitivity analyses were confirmatory with the exception of the non-significant association of LVM or LVMI with the ACE genotype in women. However, only nine studies differentiated between women and men. Third, LVM is a continuous variable under the influence of many environmental factors and lifestyle. Adjustments for these confounders were inconsistent across studies, but the comparison between ACE genotypes within individual studies was adjusted for the same determinants of LVM.
In conclusion, our findings support the hypothesis that enhanced ACE activity associated with the D allele might increase LV mass independent of blood pressure. Smaller sample size might explain the lack of significant association with LVH. Whether the association of LVM with innate ACE activity has any implications in the treatment of hypertension or preventing or regressing LVH remains to be elucidated. The issue can only be resolved by a doubleblind clinical trial, in which patients are first stratified by ACE genotype and subsequently randomised to ACE inhibitors or a reference drug that stimulates the renin system. Finally, published reports should account for changes in LVM that result from true change in wall thickness as opposed to changes in LVM that computationally result from changes in LVID.
